Measuring Blood Pressure Accurately, and What a Finger-Worn Photoplethysmograph Can Claim: A Critical Appraisal of the Oura Ring's Blood-Pressure Features

Background. Blood pressure (BP) is the most consequential modifiable cardiovascular risk factor, and its accurate measurement is a precondition of every diagnostic and therapeutic decision that follows. In 2026 the Oura Ring 5 introduced two consumer features, Blood Pressure Signals and Nighttime BP, which infer blood-pressure-related patterns from nocturnal finger photoplethysmography (PPG). Their release coincided with a revision of the US Food and Drug Administration (FDA) general wellness policy that permits non-invasive estimation of physiological parameters, including BP, outside device regulation when marketed solely for wellness. Scope. This review sets out what accurate BP measurement requires, including the reference standards, the recognised sources of error, and the validation protocols applied to cuffed devices. It then describes the physical and physiological basis of cuffless estimation and the validation framework now recommended for such devices. Against that framework it appraises the published evidence for the Oura features. Findings. Even a well-conducted cuff measurement differs from intra-arterial pressure by approximately 5–6 mmHg on average, and a device can pass the ISO 81060-2 accuracy criterion while roughly one reading in five differs from the reference by more than 10 mmHg. PPG does not sense pressure. It records a volumetric optical signal that is jointly determined by arterial pressure, vascular tone, arterial stiffness, stroke volume, temperature, perfusion, sensor contact and the hydrostatic height of the hand. At the finger, a 30 cm change in hand height relative to the heart alters local arterial pressure by about 23 mmHg, which is of the same order as the 12–24 mmHg nocturnal dip the feature purports to classify. The only performance data for Nighttime BP are company-reported: 134 participants, 48-hour ambulatory reference, sensitivity 84% and specificity 69% for identifying dippers, and an area under the curve of 0.87. These data are not peer-reviewed, do not distinguish algorithm development from independent validation, and provide no agreement statistics for the continuous percentage dip on which the four output categories depend. Read in the clinically relevant direction, the algorithm fails to identify 31% of non-dippers. No performance data have been published for Blood Pressure Signals. The associated FDA-track study uses participant-reported hypertension as its reference standard. In a Rule 433 free writing prospectus filed with the SEC on 24 September 2026, Oura’s Chief Executive describes a system that detects a six-month rise in heart rate as “unusual” and prompts the wearer “more like a doctor,” and cites “managing a chronic illness” and “monitoring your progress of a disease” as use cases. These statements sit in tension with Oura’s own disclaimers of medical-device status and disease monitoring. Conclusions. The Oura Ring does not measure blood pressure, and the company states as much. Its features classify a nocturnal PPG phenotype that correlates with ambulatory dipping status. That phenotype may prove useful, but it has not been validated against any recognised cuffless protocol, has not been independently replicated, and should not inform diagnosis, reassurance or treatment. Statements made to investors describing doctor-like surveillance and disease monitoring require the evidence appropriate to diagnostic claims, and none has been published. Clinicians should treat an Oura BP output as a prompt for properly conducted home or ambulatory measurement, never as a substitute for it.